HAOXI HEALTH TECHNOLOGY and Eaglepoint AI Forge Strategic Partnership to Enter AI-Powered Health Management Track
MWN-AI** Summary
HAOXI Health Technology Limited (NASDAQ: HAO) and Eaglepoint AI Inc., a subsidiary of Global Mofy AI Limited (NASDAQ: GMM), have entered a strategic partnership to develop an AI-powered health management platform in China. The agreement, which spans three years, involves shared resources in research and development, data management, and marketing channels, signaling HAOXI’s intent to explore opportunities within the rapidly growing AI-enabled healthcare sector.
This collaboration marks Eaglepoint AI’s initial deployment of its Aquila data engine and multimodal model evaluation system in a health-related context. The partnership aims to enhance preventive healthcare practices, focusing on applications like intelligent nutrition, chronic disease risk assessment, and digital therapeutics. HAOXI Health will leverage its extensive marketing networks to enhance user reach and commercial conversion efforts, while Eaglepoint AI will provide technical backing for model training and ensure data security compliance.
The first phase of their project will introduce the "AI Digital Health Manager," a SaaS system tailored for populations at risk of sub-health and chronic diseases. Mr. Fan Zhen, CEO of HAOXI Health, emphasized their commitment to delivering personalized health management solutions that meet client demands, noting Eaglepoint AI's expertise in data governance and algorithm efficiency.
HAOXI Health, headquartered in Beijing, specializes in online marketing solutions for the healthcare industry, primarily leveraging platforms like Toutiao and Douyin. The partnership with Eaglepoint AI is expected to enhance the digital marketing ROI for healthcare enterprises in China while developing essential health data pipelines for AI applications, thereby contributing to a competitive edge across the interconnected domains of data, algorithms, and traffic.
MWN-AI** Analysis
The recent strategic partnership between HAOXI HEALTH TECHNOLOGY (NASDAQ: HAO) and Eaglepoint AI Inc. marks a pivotal moment for both companies, particularly as they venture into the burgeoning sphere of AI-powered health management in China. This collaboration appears timely given the increasing demand for innovative healthcare solutions that leverage AI to enhance patient outcomes and operational efficiencies.
Investors should view this partnership as a catalyst for growth in HAO's core business. With a strong foundation in online marketing solutions for healthcare, HAO's ability to harness Eaglepoint AI's advanced technology, including the Aquila data engine, sets the stage for the rollout of the "AI Digital Health Manager" SaaS system. This product aims to address the needs of sub-healthy and chronic disease populations—a demographic that is particularly relevant as China grapples with an aging population and rising healthcare costs.
HAO’s strategy to utilize its established marketing networks will not only drive user acquisition but could significantly improve the return on investment for domestic healthcare enterprises seeking effective digital solutions. The integration of AI into preventive healthcare applications, like intelligent nutrition and chronic disease risk assessments, indicates a comprehensive approach to health management that is likely to resonate with consumers increasingly focused on personalized healthcare experiences.
However, potential investors should remain cautious and aware of the risks outlined in the company's forward-looking statements. Market conditions, regulatory environments, and competitive pressures could impact the projected success of this partnership. As such, while the collaboration presents significant growth potential, it is vital for investors to conduct thorough due diligence.
In summary, HAOXI HEALTH TECHNOLOGY is positioned strategically to capitalize on the AI health management trend through its partnership with Eaglepoint AI. With prudent management and execution, this could lead to enhanced market presence and sustained growth, making HAO a stock to watch in the coming years.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BEIJING, March 03, 2026 (GLOBE NEWSWIRE) -- HAOXI HEALTH TECHNOLOGY LIMITED (NASDAQ: HAO) (the “Haoxi Health”), a U.S. publicly listed company, and Eaglepoint AI Inc., a subsidiary of Global Mofy AI Limited (NASDAQ: GMM), today jointly announced the signing of a three-year strategic cooperation agreement. The two parties will jointly commit R&D, data, and channel resources to launch an AI health management platform in China. Haoxi Health believes that this partnership marks its's exploration of potential opportunities in the AI-enabled healthcare sector. This collaboration also represents the first time that Eaglepoint AI has deployed its Aquila data engine and multimodal model evaluation system in a high-growth health management scenario.
Under the agreement, both parties will explore collaboration in the AI-enabled preventive healthcare applications, including intelligent nutrition, chronic disease risk assessment, and digital therapeutics. HAOXI HEALTH plans to contribute its marketing networks to provide user reach and commercial conversion support, while Eaglepoint AI will be responsible for technical support in model training, data security compliance, and algorithm iteration. The first phase of the project will launch the "AI Digital Health Manager" SaaS system targeting sub-healthy and chronic disease populations.
Mr. Fan Zhen, CEO of Haoxi Health, stated: "The company has long served domestic and international healthcare clients, managing tens of billions of online advertising data points. We understand clients' urgent demand for personalized, quantifiable health management solutions. Eaglepoint AI possesses capabilities in data governance and multimodal model evaluation. Its proprietary Aquila platform has achieved automated comparative experiments with mainstream large models including Claude, GPT, and Gemini, improving model iteration efficiency by 3.5 times. We believe this collaboration will integrate HAOXI's marketing traffic advantages with Eaglepoint's algorithmic strengths."
Both parties believe that the collaboration between HAOXI HEALTH and Eaglepoint AI will not only enhance digital marketing ROI for domestic healthcare enterprises but also provide health data pipelines for AI models, contributing to the competitive and cooperative landscape across the "Data + Algorithm + Traffic" dimensions.
About Haoxi Health Technology Limited
Haoxi Health Technology Limited is a Beijing-headquartered online marketing solution provider in China, specializing in serving healthcare industry advertiser clients. The Company's growth is driven by the rise of news feed ads and the rapid development of the healthcare sector. The Company offers one-stop online marketing solutions, especially in online short video marketing, helping advertisers acquire and retain customers on popular platforms in China, such as Toutiao, Douyin, WeChat, and Sina Weibo. It is dedicated to reducing costs, increasing efficiency, and providing easy online marketing solutions to advertisers.
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Investor Relations
ir@haoximedia.com
FAQ**
How does the partnership between Haoxi Health and Eaglepoint AI, as detailed in the March 3, 2026 announcement, align with the investment strategy of the Invesco China Small Cap ETF, managed by Invesco Capital Management LLC HAO?
What specific features of the AI health management platform could attract interest from the Invesco China Small Cap ETF in supporting growth in Haoxi Health's market presence?
Considering the collaborative focus on AI-enabled preventive healthcare, how might this venture impact the valuation of Haoxi Health in relation to its potential inclusion in the Invesco China Small Cap ETF managed by Invesco Capital Management LLC HAO?
What risks should investors in the Invesco China Small Cap ETF, specifically related to Haoxi Health's partnership with Eaglepoint AI, be aware of in the context of the competitive healthcare landscape mentioned in their announcement?
**MWN-AI FAQ is based on asking OpenAI questions about Invesco China Small Cap ETF Invesco Capital Management LLC (NASDAQ: HAO).
NASDAQ: HAO
HAO Trading
10.55% G/L:
$1.205 Last:
662 Volume:
$1.09 Open:
